IMGN News and Press, ImmunoGen Inc. From 03/04/19

Invitae (NYSE: NVTA ) initiated with Buy rating and $29 (43% upside) price target at Chardan Capital Markets. Shares up  2%  premarket. More news on: Invitae, ImmunoGen, Inc., Zoetis, Stocks on the move, Healthcare stocks news, Read more ...

Gainers:  Bio-Path Holdings (NASDAQ: BPTH ) +130% . Puma Biotechnology (NYSE: PBYI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +30% . GlobalSCAPE (NYSEMKT: GSB ) +29% . Castlight Health (NYSE: CSLT ) +24% . Farfetch Limited (NYSE: FTCH ) +23% . Sequential Brands Group (NASD...

ImmunoGen (NASDAQ: IMGN )  -46%  after mirvetuximab soravtansine flunks late-stage study. More news on: ImmunoGen, Inc., Mersana Therapeutics, Nutanix, Stocks on the move, Read more ...

ImmunoGen (NASDAQ: IMGN ) slumps  43%  premarket on light volume (at this point) in response to its announcement that the Phase 3 FORWARD I study evaluating antibody-drug conjugate mirvetuximab soravtansine compared to chemo in folate receptor alpha-positive, platinum-resistant...

Trial Did Not Meet Primary Endpoint of Progression-Free Survival Efficacy Signal Seen in High Folate Receptor Alpha Patients; Additional Analyses to be Conducted Favorable Tolerability Profile Confirmed Combination Regimens to be Evaluated as an Independent Path Forward to Su...

Continued Innovation in ADCs Highlighted in Eleven Posters First-in-Class ADAM9-targeting ADC, IMGC936, Developed in Collaboration with MacroGenics, Demonstrates Preclinical Activity in Models of Non-Small Cell Lung, Gastric, and Colorectal Cancers Novel DARPin ® Drug Conjuga...

HENDERSON, NV / ACCESSWIRE / February 21, 2018 / The healthcare sector provides investors with some of the biggest profit opportunities in the whole market. An oversold stock in the sector we think you should know is Delcath Systems, Inc. (DCTH) . With promising liver cancer treatments in l...

The following slide deck was published by ImmunoGen, Inc. in conjunction with this Read more ...

HENDERSON, NV / ACCESSWIRE / February 14, 2019 / The biotech market has been providing investors with several profit opportunities so far this year. Below are a few companies you should research right away so you can book some profits of your own. The first stock we suggest looking at is B...

ImmunoGen, Inc. (IMGN) Q4 2018 Results Earnings Conference Call February 08, 2019 08:00 AM ET Company Participants Courtney O’Konek - Corporate Communications Mark Enyedy - President and CEO Anna Berkenblit - CMO Rich Gregory - Chief Scientific Officer Blaine Mckee - ...